Therapeutic effect of gemcitabine hydrochloride combined with stereotactic radiotherapy for locally advanced pancreatic cancer / 临床肝胆病杂志
Hongbing JI; Zhonghua CHEN.
Journal of Clinical Hepatology
; (12): 537-540, 2016.
Artículo
en Zh
| WPRIM | ID: wpr-778578
ObjectiveTo investigate the clinical therapeutic effect of gemcitabine hydrochloride combined with stereotactic radiotherapy for locally advanced pancreatic cancer. MethodsA total of 122 previously untreated patients with locally advanced pancreatic cancer who were not able to undergo surgical resection and were admitted to Fuzhou General Hospital from June 2008 to June 2013 were selected, and according to the therapies, they were divided into the group with a combination of gemcitabine hydrochloride and stereotactic radiotherapy (group A, n=56) and the group with gemcitabine therapy alone (group B, n=66). The changes in condition, toxic and side effects, and death time were recorded. The chi-square test was applied for comparison between groups, and the Kaplan-Meier method was applied for plotting survival curves. ResultsThere was a significant difference in response rate between group A and group B ［67.8% (38/56) vs 227% (15/66), χ2=25.11, P＜0.01］; the effective pain-relieving rate showed a significant difference between group A and group B (95.8% vs 77.2%, χ2=7.39, P＜0.01); there were significant differences in 1-year survival rate, 2-year survival rate, and median survival time between the two groups ［58.9% (33/56) vs 31.8% (21/66), χ2=9.03, P＜0.01; 28.6% (16/56) vs 106% (7/66), χ2=6.39, P＜0.01; 12.8 months vs 7.9 months; χ2=15.51, P＜0.01］. ConclusionGemcitabine hydrochloride combined with stereotactic radiotherapy has good short- and long-term efficacy, and toxic and side effects are tolerable.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados